arrow_back Back Filing freshness 10-Q Q1 FY2026 SEC EDGAR

CorMedix Inc.

CRMD
$7.43 ▼ -0.06 (-0.80%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
71 Visible periods
28 Metrics
Peer-ranked Benchmarks
Price Chart
94
Health
Excellent
Bullish
auto_awesome

Analytical Summary

CorMedix Inc. shows strong fundamentals with top-quartile Return on Common Equity (%) and Profit Margin (%). The company's metrics support a bullish outlook for growth-oriented investors.

Market Cap $590.8M
Dividend Yield
Revenue Growth 226.1%
Op. Margin 50.0%
ROIC 10.1%
FCF / Share $0.52
Trailing P/E 15.5x
Price / Book 1.3x
FCF Yield 7.1%
Debt / Equity
info Valuation on last close. End-of-day price, Aug 7, 2026.

71-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$127.43M
↑ +226.1%
Net Income Profit after all expenses
$38.60M
↑ +87.0%
Operating Margin Operating profit as % of sales
50.0%
↑ +8.7% 97th
FCF / Share Free cash flow per share
$0.52
↑ +73.3%
trending_up

Bullish Indicators

  • Operating Margin (%)Operating Margin (%) is in the top quartile
  • Profit Margin (%)Profit Margin (%) is in the top quartile
  • Return on Common Equity (%)Return on Common Equity (%) is in the top quartile
warning

Bearish Risks

  • No bearish risks detected.

Health Breakdown

Profitability
98
Returns
96
Financial Health
100
Cash Quality
68

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 20 years · 71 quarters